wishmeluckplz Posted - 3 hours ago

$NVNO

BigGreenCandle Posted - 1 day ago

$NVNO No room left on the train.

BigGreenCandle Posted - 5 days ago

$NVNO Needs a nudge. Get this over the 5.30 range. Nice option flow lately.

BigGreenCandle Posted - 5 days ago

$NVNO Forcing the purchase of more cheapies. Not going to complain.

BigGreenCandle Posted - 6 days ago

$NVNO Time to revisit $6 range.

wannaberetiree Posted - 6 days ago

$NVNO my favorite kind of climb. On no volume whatsoever.

BigGreenCandle Posted - 04/29/24

$NVNO You have the clearance, Clarence.

cdsnuts93 Posted - 04/29/24

$NVNO - Seems like Abbott should expand their product line and snatch up the VenoValve. https://www.webullapp.com/news-detail/10661968032765952?theme=1&hl=en&color=2&_v=1&tickerId=913254903&disSymbol=ABT&sp=0&hl=en

wishmeluckplz Posted - 04/27/24

$NVNO

brazoshound Posted - 04/27/24

$NVNO one day closer 🚀

bogwalk Posted - 04/25/24

$NVNO $55.31 no one will notice.

Rafatops Posted - 04/25/24

$NVNO a significant insider buy would send this. And I sense one or more are coming this year.

wannaberetiree Posted - 04/25/24

$NVNO there's that schizo movement we've grown fond of. Back to the 6s?

BigGreenCandle Posted - 04/25/24

$NVNO Alright. Green again.

747rasta Posted - 04/25/24

$NVNO just picked up some more @ 5. Hope this thing doesn't bite me in the azz.

Icemanja Posted - 04/24/24

$NVNO Why are they still stating cash on hand at end of Q4 2023 vs End of Q1 2024 ? " As of December 31, 2023, the Company had cash and investments of $46.4 million on hand" PR looks like a lazy copy and paste job.

Rafatops Posted - 04/24/24

$NVNO i’m going to start treating this stock like a retirement account. Adding every month, setting and forgetting.

BigGreenCandle Posted - 04/24/24

$NVNO Added some more cheapies on the down draft. How low is it going? 3.75 range again?

kmx_swing Posted - 04/24/24

$NVNO Q3 starts in 2months and 1 week

Icemanja Posted - 04/24/24

$NVNO 16k volume tells the story.

vpalani Posted - 04/24/24

$NVNO solid buy over the time many investors must have bought at warrants price this should run this week 🏃🏃

DonCorleone77 Posted - 04/24/24

$NVNO Below is also a link to a longer article via Access Wire. One quote I think is worth noting in the article that a friend pointed out to me is the following: "...It is so exciting to be achieving what was previously thought to be impossible, and to be continually raising the bar for the potential of the VenoValve. We are hopeful and determined to bring relief with the VenoValve to the millions of patients suffering from severe deep venous CVI, who have no effective treatment options." Looks like it opened today with some profit taking after yesterday's gains. Let's see where she wants to go from here. https://finance.yahoo.com/news/positive-11-month-topline-efficacy-101500197.html

DonCorleone77 Posted - 04/24/24

@MaverikIT @net0trader @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC $NVNO - Will be keeping an eye on this one today: https://stocktwits.com/DonCorleone77/message/570632698

vpalani Posted - 04/24/24

$NVNO wow top line news loaded here 🤩 with presentation today followed soon by ER $10 📈🚨🚨

Finanz Posted - 04/24/24

$NVNO Impressive clinical trial results.

DonCorleone77 Posted - 04/24/24

$NVNO Momma sure wants some new shoes...Let;s see if she get them!! enVVeno Medical presents topline efficacy data from SAVVE trial enVVeno Medical announced the presentation of topline efficacy data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 Charing Cross International Symposium in London, UK. The data being presented shows that for patients experiencing a Clinical Meaningful Benefit, the overall average rVCSS improvement was 8.46 points, including 9.29 points for patients at the two-year milestone, 8.08 points for patients at the one-year milestone, and 8.71 points for patients at the six-month milestone. All rVCSS evaluations were based on the patient's most recent clinical visit, compared to baseline, for a weighted average of eleven months following VenoValve implantation for the Clinical Meaningful Benefit patient cohort. Overall, 94% of the study patients receiving the VenoValve have shown clinical improvement as measured by rVCSS at a weighted-average patient follow-up of 11.04 months for the clinical improvement cohort, and 72% of the study patients have improved the three or more rVCSS points needed to demonstrate the VenoValve's Clinical Meaningful Benefit, at a weighted-average patient follow-up of 11.64 months for the Clinical Meaningful Benefit cohort. Total patient follow-up was 762 months and 582 months, respectively, for the two patient cohorts.

laste_rounde Posted - 04/24/24

$NVNO Outstanding results. Not sure you can get much better.

Stock_Titan Posted - 04/24/24

$NVNO Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium https://www.stocktitan.net/news/NVNO/positive-11-month-topline-efficacy-data-showing-significant-clinical-qwukyqs230jl.html

Stockboa Posted - 04/23/24

$NVNO Does anyone know when/what time they are presenting at the conference?

Bunti Posted - 04/23/24

$NVNO Wow should check my old account!!!